Inovio Pharmaceuticals Files Material Definitive Agreement
Ticker: INO · Form: 8-K · Filed: Aug 13, 2024 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $60,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: INO
TL;DR
INOVIO just signed a big deal, details TBD.
AI Summary
On August 13, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing does not provide specific details on the agreement or any associated dollar amounts or parties involved.
Why It Matters
This filing indicates a significant new contract or partnership for Inovio Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.
Key Players & Entities
- Inovio Pharmaceuticals, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement filed by Inovio Pharmaceuticals?
The 8-K filing does not specify the nature of the material definitive agreement.
Who are the parties involved in the material definitive agreement?
The filing does not disclose the names of the parties involved in the agreement.
Are there any financial terms or dollar amounts associated with this agreement?
The filing does not provide any specific financial terms or dollar amounts related to the agreement.
When was the material definitive agreement entered into?
The filing reports the agreement as of August 13, 2024, but the exact date of entry is not specified.
What is the purpose of this 8-K filing?
The purpose of this 8-K filing is to report the entry into a material definitive agreement by Inovio Pharmaceuticals, Inc.
Filing Stats: 870 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-08-13 06:06:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $60,000,000 — ng an aggregate offering price of up to $60,000,000. Subject to the terms and conditions
Filing Documents
- d761691d8k.htm (8-K) — 29KB
- d761691dex11.htm (EX-1.1) — 158KB
- d761691dex51.htm (EX-5.1) — 9KB
- g761691g49p02.jpg (GRAPHIC) — 3KB
- 0001193125-24-199331.txt ( ) — 369KB
- ino-20240813.xsd (EX-101.SCH) — 3KB
- ino-20240813_lab.xml (EX-101.LAB) — 18KB
- ino-20240813_pre.xml (EX-101.PRE) — 11KB
- d761691d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Equity Distribution Agreement, dated August 13, 2024, by and between Inovio Pharmaceuticals, Inc. and Oppenheimer & Co. Inc. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: August 13, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer